Genetically engineered and self-assembled oncolytic protein nanoparticles for targeted cancer therapy.
Biomaterials
; 120: 22-31, 2017 03.
Article
en En
| MEDLINE
| ID: mdl-28024232
The integration of a targeted delivery with a tumour-selective agent has been considered an ideal platform for achieving high therapeutic efficacy and negligible side effects in cancer therapy. Here, we present engineered protein nanoparticles comprising a tumour-selective oncolytic protein and a targeting moiety as a new format for the targeted cancer therapy. Apoptin from chicken anaemia virus (CAV) was used as a tumour-selective apoptotic protein. An EGFR-specific repebody, which is composed of LRR (Leucine-rich repeat) modules, was employed to play a dual role as a tumour-targeting moiety and a fusion partner for producing apoptin nanoparticles in E. coli, respectively. The repebody was genetically fused to apoptin, and the resulting fusion protein was shown to self-assemble into supramolecular repebody-apoptin nanoparticles with high homogeneity and stability as a soluble form when expressed in E. coli. The repebody-apoptin nanoparticles showed a remarkable anti-tumour activity with negligible side effects in xenograft mice through a cooperative action of the two protein components with distinct functional roles. The repebody-apoptin nanoparticles can be developed as a systemic injectable and tumour-selective therapeutic protein for targeted cancer treatment.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Ingeniería de Proteínas
/
Proteínas de la Cápside
/
Nanopartículas
/
Terapia Molecular Dirigida
/
Neoplasias Experimentales
Límite:
Animals
/
Humans
/
Male
Idioma:
En
Revista:
Biomaterials
Año:
2017
Tipo del documento:
Article
País de afiliación:
Corea del Sur
Pais de publicación:
Países Bajos